Attention shifts to the white clot

Lancet

Volumn 350, Issue SUPPL.3, 1997, Pages

  Narins, Craig R ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; HUMAN; REVIEW;

CARDIOVASCULAR DISEASES; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0002190593     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)90035-0     Document Type: Article

References (5)

1. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997; 95: 846-54.
2. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-35.
3. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor inhibition with abciximab with lower heparin dosages during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
4. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifidatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422-28.
5. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomised trial of brief integrin beta 3 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479-84.